Ki Bum Hong

Dr. Ki Bum Hong

DGMIF
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KHKi Bum Hong
Ki Bum Hong
HAHongchan An
Hongchan An

19 July 2019 in Molecules
Verified
Journal Article
Open access
PDF file
JLJi Hoon Lee
Ji Hoon Lee
SCSungwook Choi
Sungwook Choi
KHKi Bum Hong
Ki Bum Hong
Hypervalent iodine reagents are of considerable relevance in organic chemistry as they can provide a complementary reaction strategy to the use of traditional transition metal chemistry. Over the past two decades, there have been an increasing number of applications including stoichiometric oxidation and catalytic asymmetric variations. This review outlines the main advances in the past 10 years in regard to alkene heterofunctionalization chemistry using achiral and chiral hypervalent iodine reagents and catalysts.

10 November 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
NYNam Gu Yoon
Nam Gu Yoon
HLHakbong Lee
Hakbong Lee
SKSo-Yeon Kim
So-Yeon Kim
SHSung Hu
Sung Hu
DKDarong Kim
Darong Kim
BKByoung Heon Kang
Byoung Heon Kang

8 May 2023 in Organic Letters
Verified
Journal Article
Closed access
YCYe Rin Choi
Ye Rin Choi
SLSeok Beom Lee
Seok Beom Lee
JLJae Kyun Lee
Jae Kyun Lee
YKYoonna Kwak
Yoonna Kwak
HAHongchan An
Hongchan An
KHKi Bum Hong
Ki Bum Hong

2 May 2020 in Biology
Verified
Journal Article
Open access
PDF file
SLSeul Lee
Seul Lee
DWDong‐Cheol Woo
Dong‐Cheol Woo
JKJeeheon Kang
Jeeheon Kang
MRMoonjin Ra
Moonjin Ra
Ki Hyun KimKi Hyun Kim
Ki Hyun Kim
JYJi Hoon Yu
Ji Hoon Yu
Non-alcoholic fatty liver disease (NAFLD) is a leading form of chronic liver disease, with few biomarkers and treatment options currently available. Non-alcoholic steatohepatitis (NASH), a progressive disease of NAFLD, may lead to fibrosis, cirrhosis, and hepatocellular carcinoma. Epigenetic modification can contribute to the progression of NAFLD causing non-alcoholic steatohepatitis (NASH), in which the exact role of epigenetics remains poorly understood. To identify potential therapeutics for NASH, we tested small-molecule inhibitors of the epigenetic target histone methyltransferase EZH2, Tazemetostat (EPZ-6438), and UNC1999 in STAM NASH mice. The results demonstrate that treatment with EZH2 inhibitors decreased serum TNF-alpha in NASH. In this study, we investigated that inhibition of EZH2 reduced mRNA expression of inflammatory cytokines and fibrosis markers in NASH mice. In conclusion, these results suggest that EZH2 may present a promising therapeutic target in the treatment of NASH.

11 January 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EPEunsun Park
Eunsun Park
SLSun Joo Lee
Sun Joo Lee
HMHeegyum Moon
Heegyum Moon
JPJongmi Park
Jongmi Park
HJHyeonho Jeon
Hyeonho Jeon
SKSOO SUNG Kang
SOO SUNG Kang